文献速递外周动脉疾病

低径4-F支架治疗动脉粥样硬化性髂动脉疾病的中期结果

Midterm Results of Low-Profile Stents to Treat Atherosclerotic Iliac Artery Disease.
PubMed 文献 · J Endovasc Ther · 2017-01-01

单中心回顾性研究纳入63例(82处病变)动脉粥样硬化性髂动脉闭塞性疾病患者,置入低径4-F支架。4年一期通畅率76.9%,免于靶病变血运重建率73.8%,Rutherford 5/6级与通畅率差独立相关。

要点

  • 低径4-F支架治疗髂动脉病变安全有效,4年通畅率良好
  • Rutherford 5/6级患者中期通畅率较差
  • 推荐使用直径≥6 mm支架并常规行后扩张

核心结论

  • 低径4-F支架治疗动脉粥样硬化性髂动脉病变安全有效,4年总体通畅率和免于TLR率良好。
  • Rutherford 5/6级缺血患者中期结局较差。
  • 推荐使用直径≥6 mm的支架并在所有病例中行后扩张。

研究设计与样本

  • 63.5%(40例)患者为严重肢体缺血,82处病变中36处为完全闭塞。
  • 所有手术均使用4-F器械,通过肱动脉(46/63)或股动脉(17/63)入路完成。

主要发现

  • 82枚支架成功置入82处病变,残余狭窄<30%。
  • 入路相关并发症发生率为1.6%(1例肱动脉闭塞)。
  • 平均随访24.1±22.3个月(范围1-72个月),期间3例死亡,1例于10个月时行大截肢。
  • 4年Kaplan-Meier估计一期通畅率为76.9%(95%CI 70.2%-83.6%),辅助一期通畅率为79.3%(95%CI 73%-85.6%),二期通畅率为91%(95%CI 84.5%-97.5%)。
  • 4年免于TLR率为73.8%(95%CI 67.4%-80.2%)。

关键数值与推荐

  • 推荐使用直径≥6 mm的支架。
  • 推荐在所有病例中行支架置入后球囊扩张。

临床怎么用

  • 对于动脉粥样硬化性髂动脉病变,可考虑使用低径4-F支架,尤其适合经肱动脉入路。
  • 应选用直径≥6 mm的支架并常规行后扩张。
  • 对Rutherford 5/6级患者应加强随访,预期通畅率较低。

局限性

  • 回顾性单中心研究,样本量较小(63例)。
  • 支架类型由术者决定,存在选择偏倚。
  • 随访时间不一致,部分患者失访可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and effectiveness of low-profile 4-F stents for the treatment of atherosclerotic iliac artery lesions. METHODS: Between January 2009 and December 2015, 63 patients (mean age 69.3 years; 42 men) received low-profile stents (Astron Pulsar or Pulsar-18) at the discretion of the operator to treat iliac artery occlusive disease. The majority of patients (40, 63.5%) had critical limb ischemia; 36 of 82 lesions were total occlusions. All procedures were performed with 4-F equipment. Outcomes evaluated included mortality, patency (primary, assisted primary, and secondary), absence of target lesion revascularization (TLR), and limb salvage. Associations of patient and procedure variables with patency and TLR outcomes were sought with univariate and multivariate analysis. RESULTS: Via a brachial (n=46/63) or femoral (n=17/63) access, 82 stents were successfully deployed to treat the 82 lesions, with <30% residual stenosis. The overall access-related complication rate was 1.6% (brachial artery occlusion). Mean duration of follow-up was 24.1±22.3 months (range 1-72), during which 3 patients died and 1 major amputation occurred at 10 months. The 4-year Kaplan-Meier estimate of primary patency was 76.9% (95% CI 70.2% to 83.6%); the assisted primary and secondary patency estimates were 79.3% (95% CI 73% to 85.6%) and 91% (95% CI 84.5% to 97.5%). The 4-year freedom from TLR estimate was 73.8% (95% CI 67.4% to 80.2%). On multivariate analysis, the only associations confirmed involved Rutherford category 5/6 with primary patency (hazard ratio [HR] 5.7, 95% CI 4.4 to 7, p=0.02) and assisted primary patency (HR 6.1, 95% CI 4.9 to 7.3, p=0.01). CONCLUSION: Use of a low-profile 4-F stent in atherosclerotic iliac lesions was safe and effective. At 4 years, the overall patency and the absence of TLR were good. Midterm outcomes were poor in patients with Rutherford category 5/6 ischemia. Finally, the use of stents with a ≥6-mm diameter and postdeployment balloon dilation are recommended in all cases.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Troisi N, Ercolini L, Chisci E, et al. Midterm Results of Low-Profile Stents to Treat Atherosclerotic Iliac Artery Disease. J Endovasc Ther. 2017. PMID: 28511618. doi:10.1177/1526602817704827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。